Semaglutide
Also known as Ozempic · Wegovy · Rybelsus
New
Reconstitution & dosing guide
2 mg · 5 mg · 10 mg · 15 mg · 20 mg · 50 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
Semaglutide (SM10) · Not in current stock
$40 / vial
15mg x 10 vials
Semaglutide (SM15) · Not in current stock
$60 / vial
2mg x 10 vials
Semaglutide (SM2) · Not in current stock
$20 / vial
20mg x 10 vials
Semaglutide (SM20) · Not in current stock
$75 / vial
5mg x 10 vials
Semaglutide (SM5) · Not in current stock
$25 / vial
50mg x 10 vials
Semaglutide (SM50) · Not in current stock
$165 / vial
Prices per vial · Research use only · Not medical advice.
Long-acting GLP-1 receptor agonist; FDA-approved for type 2 diabetes and chronic weight management.
How to picture it
After a meal, your gut releases GLP-1, a short-lived "we're fed" hormone. Semaglutide is a long-acting copy that keeps knocking on GLP-1 receptors in brain and pancreas: appetite circuits quiet down, stomach empties slower, and insulin response is supported when glucose is up. Picture a fed-state message that doesn't fade in minutes the way natural GLP-1 does — durable satiety and glycemic coaching with extensive clinical literature in the class.
Research focus & benefits
- Appetite reduction and weight-management research
- Glycemic control pathway literature
- Gastric emptying and satiety signaling studies
- Extensive human clinical data in the drug class
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glycemic control. Brand products (Ozempic, Wegovy, Rybelsus) transformed metabolic medicine and flooded biohacking discourse. Compounded and gray-market versions raise safety and legality issues.
Mechanism
GLP-1 receptor agonism in brain and gut reduces hunger and postprandial glucose excursions; promotes weight loss primarily via reduced energy intake.
Research uses
- Type 2 diabetes
- Obesity / chronic weight management
- Cardiovascular risk reduction (approved contexts)
- Exploratory addiction and NASH research
Research dosing notes
Approved products use carefully titrated weekly subcutaneous dosing (or daily oral Rybelsus). Self-directed high doses increase GI adverse events. Medical supervision is standard of care.
Half-life / kinetics
~1 week (weekly injection formulations)
Common research routes
Reported considerations
- Nausea, vomiting, constipation/diarrhea
- Gallbladder issues
- Muscle loss if protein/training neglected
- Rare pancreatitis / thyroid C-cell tumor warnings per label
Contraindications / cautions
- Personal/family history of MTC or MEN2
- Pregnancy
- History of pancreatitis (caution)
- Severe GI disease
Common research stacks
- Protein-forward diet + resistance training
- Sometimes discussed with other incretins (clinic only)
Legal / access note
FDA-approved as prescription medicine for defined indications. Counterfeit and unapproved compounded products have been a major safety issue.